Healthcare Unfiltered Express

In this special episode of the Healthcare Unfiltered EXPRESS, I am joined by Meghan Gutierrez, the CEO of the foundation who shares the vision and mission of this non-for-profit organization. How does the LRF support research and how does it help patients and caregivers? What should we look for in the future?This is an excellent episode with a wonderful leader who strives to help patients by leading a marvelous organization destined to make a difference in the lives of people affected by lymphoma.Please subscribe and join the conversation

Dr. Edward Pearson, a community oncologist in Texas, shares on #HealthcareUnfiltered EXPRESS, pearls of wisdom on how best to manage bispecific antibodies in the community setting. He explains what these agents are—which are changing cancer treatment— as well as when and why to use them, and how to ensure their safe delivery in the community oncology setting where most patients receive care.This is a must-listen and must-watch episode. Please share and join the conversation.

The World Congress on Lung Cancer in Seoul has just concluded, and the insightful Dr. Chul Kim of Georgetown University and Medstar Health joined #HealthcareUnfiltered EXPRESS to share his valuable opinions on practice changing/informing data presented at the meeting.Please share, subscribe, and join the conversation.

Pranav Rajpurkar, co-founder of A2Z Radiology, joins Healthcare Unfiltered EXPRESS to discuss the current—and future—state of AI in radiology. How will AI transform the field? What will it mean for radiologists, physicians, and patients? And where is all of this headed?With AI reshaping nearly every corner of healthcare, this is a conversation you won’t want to miss.Listen, share, rate, and please subscribe!

Dr. Gilberto Lopes, senior author on a recent Lancet publication addressing alcohol and cancer, joins the show to share the findings of hs group research, and the broader implications of alcohol and various cancers. Is there a safe level for alcohol use? What cancers might alcohol cause? What are the proper recommendations for patients?All of this and more on this new episode of Healthcare Unfiltered EXPRESS.Please share, subscribe, and join the conversation.Read the article.https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00229-2/fulltext

Dr. Bishoy Flatas, a pioneer in bladder cancer research at Cornell, joins the show to highlight his work on AI Tumor Twins and his in-silico model for predicting which drugs may be more effective for certain bladder cancers, optimizing clinical trial execution. Bishoy was recently interviewed on CBS News, and that segment garnered over 22 million views.This is a must listen from this innovator and trailblazer. Please share, subscribe, and join the conversation.Link to CBS News: https://x.com/CBSNews/status/2083295365353107461

I am joined by the amazing Dr. Paul Richardson from the Dana-Farber Cancer Institute to discuss the SUCCESSOR trial that was presented at EHA. This trial discusses CELMoDs by highlighting a landmark randomized Phase 3 clinical study evaluating the oral medication mezigdomide combined with carfilzomib and dexamethasone (MeziKd) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma. Results show the regimen significantly improves progression-free survival.Dr. Richardson puts this data into perspective. A must-watch on YouTube and listen here

Dr. Bruna Pellini of Baptist Health Miami Cancer Institute joins Healthcare Unfiltered EXPRESS to break down the most important lung cancer data presented at ASCO 2026. Together, we discuss the trials most likely to influence clinical practice, what they mean for patients today, and how they may reshape future treatment decisions. Watch on YouTube, subscribe, share, review, and join the conversation.

Hot off the press, the ENDURANCE trial was JUST published in NEJM. This trial explored whether patients with newly diagnosed myeloma benefit from long-term maintenance lenalidomide versus 2-years only. Dr. Vincent Rajkumar, senior author on the paper, shares the findings and context. Please subscribe, share, and join the conversation. 

Dr. Amer Zeidan joins the Healthcare Unfiltered EXPRESS to discuss the recently published KOMET-007 trial, which made its way to print in Blood. Dr. Zeidan discusses how Menin inhibitors are transforming how we approach AML like no other therapies before. What does the future hold and how will the results of this trial affect therapy? The KOMET-007 trial is a Phase 1/2 clinical study evaluating the targeted Menin inhibitor ziftomenib in combination with standard-of-care chemotherapies for acute myeloid leukemia (AML) patients with NPM1 mutations or KMT2A rearrangements. A must listen - please share subscribe, and join the conversation.